Pasar al contenido principal

DETERMINANTES MECANICOS DE LA MIGRACION CELULAR Y LA INMUNIDAD

SAF2014-54705-R

•
Nombre agencia financiadora Ministerio de Economía y Competitividad
Acrónimo agencia financiadora MINECO
Programa Programa Estatal de I+D+i Orientado a los Retos de la Sociedad
Convocatoria Proyectos I+D+i Retos de Investigación
Año convocatoria 2014
Plan Estatal 2013-2016 Plan Estatal de Investigación Científica y Técnica y de Innovación
Unidad de gestión Secretaría de Estado de Educación, Formación Profesional y Universidades
Centro beneficiario UNIVERSIDAD AUTONOMA DE MADRID
Identificador persistente http://dx.doi.org/10.13039/501100003329

Resultados relacionados

Resultados totales (Incluyendo duplicados): 8
Encontrada(s) 1 página(s)

Repisalud
Publicación Artículo científico (JournalArticle)

Activation of the orphan receptor GPR55 by lysophosphatidylinositol promotes metastasis in triple-negative breast cancer.

  • Andradas, Clara
  • Blasco-Benito, Sandra
  • Castillo-Lluva, Sonia
  • Dillenburg-Pilla, Patricia
  • Diez-Alarcia, Rebeca
  • Juanes-García, Alba
  • García-Taboada, Elena
  • Hernando-Llorente, Rodrigo
  • Soriano, Joaquim
  • Hamann, Sigrid
  • Wenners, Antonia
  • Alkatout, Ibrahim
  • Klapper, Wolfram
  • Rocken, Christoph
  • Bauer, Maret
  • Arnold, Norbert
  • Quintanilla, Miguel
  • Megías, Diego
  • Vicente-Manzanares, Miguel
  • Urigüen, Leyre
  • Gutkind, J Silvio
  • Guzmán, Manuel
  • Pérez-Gómez, Eduardo
  • Sánchez, Cristina
The orphan G protein-coupled receptor GPR55 has been directly or indirectly related to basic alterations that drive malignant growth: uncontrolled cancer cell proliferation, sustained angiogenesis, and cancer cell adhesion and migration. However, little is known about the involvement of this receptor in metastasis. Here, we show that elevated GPR55 expression in human tumors is associated with the aggressive basal/triple-negative breast cancer population, higher probability to develop metastases, and therefore poor patient prognosis. Activation of GPR55 by its proposed endogenous ligand lysophosphatidylinositol confers pro-invasive features on breast cancer cells both in vitro and in vivo. Specifically, this effect is elicited by coupling to Gq/11 heterotrimeric proteins and the subsequent activation, through ERK, of the transcription factor ETV4/PEA3. Together, these data show that GPR55 promotes breast cancer metastasis, and supports the notion that this orphan receptor may constitute a new therapeutic target and potential biomarker in the highly aggressive triple-negative subtype.
DIGITAL.CSIC. Repositorio Institucional del CSIC
Publicación Artículo científico (JournalArticle)

Activation of the orphan receptor GPR55 by lysophosphatidylinositol promotes metastasis in triple-negative breast cancer

  • Andradas, Clara
  • Quintanilla, Miguel
  • Megías, Diego
  • Pérez-Gómez, Eduardo
  • Sánchez, Cristina
et al., The orphan G protein-coupled receptor GPR55 has been directly or indirectly related to basic alterations that drive malignant growth: uncontrolled cancer cell proliferation, sustained angiogenesis, and cancer cell adhesion and migration. However, little is known about the involvement of this receptor in metastasis. Here, we show that elevated GPR55 expression in human tumors is associated with the aggressive basal/triple-negative breast cancer population, higher probability to develop metastases, and therefore poor patient prognosis. Activation of GPR55 by its proposed endogenous ligand lysophosphatidylinositol confers pro-invasive features on breast cancer cells both in vitro and in vivo. Specifically, this effect is elicited by coupling to G heterotrimeric proteins and the subsequent activation, through ERK, of the transcription factor ETV4/PEA3. Together, these data show that GPR55 promotes breast cancer metastasis, and supports the notion that this orphan receptor may constitute a new therapeutic target and potential biomarker in the highly aggressive triple-negative subtype., This work was supported by grants from Spanish Ministry of Economy and Competitiveness [PI11/00295 to CS, PI14/01101 to CS and EP-G, SAF2013-46183-R to MQ, and SAF2014-54705-R to MV-M, supported with European Regional Development (FEDER) funds] and Madrid Regional Government (S2010/BMD-2308 to MG, and 2010/ BMD-2359 to MQ). EPG was a recipient of a Postdoctoral Research Contract from Fundación Científica Asociación Española Contra el Cáncer and a Federation of the Societies of Biochemistry and Molecular Biology (FEBS) Short-term Fellowship. SB-B and SC-L are recipients of a Formación de Profesorado Universitario (FPU) fellowship and a Ramón y Cajal research contract, respectively, from the Spanish Ministry of Economy and Competitiveness., Peer Reviewed
DIGITAL.CSIC. Repositorio Institucional del CSIC
Publicación Artículo científico (JournalArticle)

Dasatinib reversibly disrupts endothelial vascular integrity by increasing non-muscle myosin II contractility in a ROCK-dependent manner

  • Kreutzman, Anna
  • Colom-Fernández, Beatriz
  • Marcos Jiménez, Ana
  • Ilander, Mette
  • Cuesta-Mateos, Carlos
  • Pérez-García, Yaiza
  • Delgado Arévalo, Cristina
  • Brück, Oscar
  • Hakanen, Henna
  • Saarela, Jani
  • Ortega-Carrión, Alvaro
  • Rosendo, Ana de
  • Juanes-García, Alba
  • Steegmann, Juan Luis
  • Mustjoki, Satu
  • Vicente-Manzanares, Miguel
  • Muñoz-Calleja, Cecilia
[Purpose]: Dasatinib is a short-acting dual ABL/SRC family tyrosine kinase inhibitor (TKI), which is frequently used to treat chronic myeloid leukemia. Although very effective, patients taking dasatinib often display severe adverse effects, including pleural effusions and increased risk of bleeding primarily in the gastrointestinal tract. The actual causes of these side effects are currently undetermined. We hypothesize that endothelial cells (ECs) that line the inner walls of blood vessels and control the traffic to the underlying tissues might be involved. [Experimental Design]: The effects of TKIs on ECs were studied by various assays, such as real-time cell impedance measurements, live-cell microscopy, wound healing, Western blot, and an in vivo model. [Results]: Dasatinib uniquely causes a profound, dose-dependent disorganization of the EC monolayers. Dasatinib promoted the disassembly of cell–cell contacts, altered cell–matrix contacts, and further altered the wound healing. A key observation is that this effect is fully reversible after drug washout. In line with these in vitro observations, intraperitoneal administration of dasatinib to mice caused significant vascular leakage in the intestine. The underlying molecular mechanism of dasatinib-induced reorganization of the actin involves ROCK activation, which increases the amount of the phosphorylation of myosin light chain and consequently activates the non-muscle myosin II. [Conclusions]: Our data are consistent with a scenario in which dasatinib triggers a transient increase in vascular leakage that probably contributes to adverse effects such as bleeding diathesis and pleural effusions., A. Kreutzman is a Sigrid Jusélius postdoctoral fellow. Grants PI12/00494P and PI15/02085 from the Fondo de Investigaciones Sanitarias to C. Muñoz-Calleja supported this work. C. Muñoz-Calleja was co-financed by FEDER funds. M. Vicente-Manzanares is an investigator from the Ramon y Cajal Program (RYC-2010-06094) and is supported by grants SAF2014-54705-R from MINECO, Marie Curie CIG-293719 from the EU, CIVP16A1831 from Ramon Areces Foundation and the BBVA Foundation. S. Mustjoki is supported by the Finnish Cancer Institute, Academy of Finland, Sigrid Juselius Foundation and Finnish Cancer Associations., Peer Reviewed
DIGITAL.CSIC. Repositorio Institucional del CSIC
Publicación Otros (Other)

Nonmuscle myosin II

  • Juanes-García, Alba
  • Llorente-González, Clara
  • Vicente-Manzanares, Miguel
The discovery of nonmuscle myosin II (NMII) is linked to the story of muscle contraction (reviewed in Szent-Gyorgyi 2004). It started in 1864,..., This work was funded by grant SAF2014-54705-R from MINECO. Miguel Vicente-Manzanares is a Ramon y Cajal Assistant Professor (RYC2010-06094)., Peer Reviewed
DIGITAL.CSIC. Repositorio Institucional del CSIC
Publicación Artículo científico (JournalArticle)

Linking the landscape of MYH9-related diseases to the molecular mechanisms that control non-muscle myosin II-A function in cells

  • Asensio-Juárez, Gloria
  • Llorente-González, Clara
  • Vicente-Manzanares, Miguel
This article belongs to the Special Issue Actin-Myosin Cytoskeleton Regulation and Function., The MYH9 gene encodes the heavy chain (MHCII) of non-muscle myosin II A (NMII-A). This is an actin-binding molecular motor essential for development that participates in many crucial cellular processes such as adhesion, cell migration, cytokinesis and polarization, maintenance of cell shape and signal transduction. Several types of mutations in the MYH9 gene cause an array of autosomal dominant disorders, globally known as MYH9-related diseases (MYH9-RD). These include May-Hegglin anomaly (MHA), Epstein syndrome (EPS), Fechtner syndrome (FTS) and Sebastian platelet syndrome (SPS). Although caused by different MYH9 mutations, all patients present macrothrombocytopenia, but may later display other pathologies, including loss of hearing, renal failure and presenile cataracts. The correlation between the molecular and cellular effects of the different mutations and clinical presentation are beginning to be established. In this review, we correlate the defects that MYH9 mutations cause at a molecular and cellular level (for example, deficient filament formation, altered ATPase activity or actin-binding) with the clinical presentation of the syndromes in human patients. We address why these syndromes are tissue restricted, and the existence of possible compensatory mechanisms, including residual activity of mutant NMII-A and/or the formation of heteropolymers or co-polymers with other NMII isoforms., This Perspective is based on research funded by Programa de Apoyo a Planes Estratégicos de Investigación de Estructuras de Investigación de Excelencia (CLC–2017–01) from the Castilla–León government and FEDER funds; SAF2014-54705-R and SAF2017-87408-R from MINECO; CIVP16A1831 from the Ramón Areces Foundation, 14-BBM-340 from the BBVA Foundation and IDEAS-VICE18 from the AECC., Peer reviewed
DIGITAL.CSIC. Repositorio Institucional del CSIC
Publicación Artículo científico (JournalArticle)

Tyrosine phosphorylation of the myosin regulatory light chain controls non-muscle myosin II assembly and function in migrating cells

  • Aguilar-Cuenca, Rocio
  • Llorente-González, Clara
  • Chapman, Jessica R.
  • Talayero, Vanessa C.
  • Garrido-Casado, Marina
  • Delgado Arévalo, Cristina
  • Millán-Salanova, María
  • Shabanowitz, Jeffrey
  • Hunt, Donald F.
  • Sellers, James R.
  • Heissler, Sarah M.
  • Vicente-Manzanares, Miguel
Active non-muscle myosin II (NMII) enables migratory cell polarization and controls dynamic cellular processes, such as focal adhesion formation and turnover and cell division. Filament assembly and force generation depend on NMII activation through the phosphorylation of Ser19 of the regulatory light chain (RLC). Here, we identify amino acid Tyr (Y) 155 of the RLC as a novel regulatory site that spatially controls NMII function. We show that Y155 is phosphorylated in vitro by the Tyr kinase domain of epidermal growth factor (EGF) receptor. In cells, phosphorylation of Y155, or its phospho-mimetic mutation (Glu), prevents the interaction of RLC with the myosin heavy chain (MHCII) to form functional NMII units. Conversely, Y155 mutation to a structurally similar but non-phosphorylatable amino acid (Phe) restores the more dynamic cellular functions of NMII, such as myosin filament formation and nascent adhesion assembly, but not those requiring stable actomyosin bundles, e.g., focal adhesion elongation or migratory front-back polarization. In live cells, phospho-Y155 RLC is prominently featured in protrusions, where it prevents NMII assembly. Our data indicate that Y155 phosphorylation constitutes a novel regulatory mechanism that contributes to the compartmentalization of NMII assembly and function in live cells., C.L.-G. is supported by a predoctoral fellowship from the Junta de Castilla y León. M.M.-S. is supported by a predoctoral fellowhip from the AECC. This work was funded by the following grants: Programa de Apoyo a Planes Estratégicos de Investigación de Estructuras de Investigación de Excelencia (CLC–2017–01) from the Junta de Castilla-León with FEDER funds (Spain); SAF2014-54705-R and SAF2017-87408-R from MINECO (Spain); CIVP16A1831 from the Ramón Areces Foundation (Spain); 14-BBM-340 from the BBVA Foundation (Spain); and IDEAS-VICE18 from the Asociacion Española Contra el Cáncer (AECC, Spain) to M.V.-M.; NIH GM 037537 (D.F.H.); and K22HL131869 (S.M.H.) and the Intramural Research Program (J.R.S.) of the National Heart, Lung, and Blood Institute, NIH., Peer reviewed
DIGITAL.CSIC. Repositorio Institucional del CSIC
Publicación Artículo científico (JournalArticle)

Adhesive Interactions Delineate the Topography of the Immune Synapse

  • Martín-Cófreces, Noa Beatriz
  • Vicente-Manzanares, Miguel
  • Sánchez-Madrid, Francisco
© 2018 Martín-Cófreces, Vicente-Manzanares and Sánchez-Madrid., T cells form adhesive contacts with antigen-presenting cells (APCs) as part of the normal surveillance process that occurs in lymph nodes and other tissues. Most of these adhesive interactions are formed by integrins that interact with ligands expressed on the surface of the APC. The interactive strength of integrins depends on their degree of membrane proximity as well as intracellular signals that dictate the conformation of the integrin. Integrins appear in different conformations that endow them with different affinities for their ligand(s). Integrin conformation and thus adhesive strength between the T cell and the APC is tuned by intracellular signals that are turned on by ligation of the T cell receptor (TCR) and chemokine receptors. During the different stages of the process, integrins, the TCR and chemokine receptors may be interconnected by the actin cytoskeleton underneath the plasma membrane, forming a chemical and physical network that facilitates the spatiotemporal dynamics, positioning, and function of these receptors and supports cell-cell adhesion during T cell activation, allowing it to perform its effector function., This manuscript has been funded by grants SAF2014-55579-R and SAF 2017-82886-R (FS-M) and SAF2014-54705-R and SAF2017-87408-R (MV-M) from the Spanish Ministry of Economy and Competitiveness; CAM S2017/BMD-3671 from the Comunidad de Madrid (FS-M); ERC-2011-AdG294340-GENTRIS (FS-M); and 2018-IDEAS18018VICE from the Asociación Española contra el Cáncer (MV-M).
DIGITAL.CSIC. Repositorio Institucional del CSIC
Publicación Artículo científico (JournalArticle)

Targeting the integrin interactome in human disease

  • Vicente-Manzanares, Miguel
  • Sánchez-Madrid, Francisco
Integrins comprise one of the most important families of cell–cell or cell–matrix adhesion receptors. Integrin interaction with their extracellular ligands is tunable by microenvironment signals, such as chemokines and growth factors, which modulate their interaction with other transmembrane proteins and cytoplasmic interactors. Integrins are important in different disease contexts, particularly inflammatory diseases and cancer. Clinical trials targeting integrins began in the early 2000s, leading to an increasingly clear picture: agents against integrins and their interactome control inflammatory diseases; whereas their efficacy as anti-cancer targets remains dubious. Here, we discuss the success of integrin targeting to treat autoimmunity and its failure in cancer, which is rooted in the plasticity and adaptability of the cancer cell., MV-M acknowledges funding from the Spanish Ministry of Economy and Innovation (MINECO), Grants SAF2014-54705-R and SAF2017-84708-R and from the Universidad de Salamanca (title XI). FS-M research is funded by grants from the Spanish Ministry of Economy and Competitiveness (Grants SAF2014-55579-R and SAF2017-82886-R), CIBER CARDIOVASCULAR from the Instituto de Salud Carlos III (Fondo de Investigación Sanitaria del Instituto de Salud Carlos III with co-funding from the Fondo Europeo de Desarrollo Regional; FEDER), Programa de Actividades en Biomedicina de la Comunidad de Madrid-B2017/BMD-3671-INFLAMUNE and ERC-2011-AdG294340-GENTRIS.